319 related articles for article (PubMed ID: 34327122)
1. Novel approaches in schizophrenia-from risk factors and hypotheses to novel drug targets.
Ľupták M; Michaličková D; Fišar Z; Kitzlerová E; Hroudová J
World J Psychiatry; 2021 Jul; 11(7):277-296. PubMed ID: 34327122
[TBL] [Abstract][Full Text] [Related]
2. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities.
Krogmann A; Peters L; von Hardenberg L; Bödeker K; Nöhles VB; Correll CU
CNS Spectr; 2019 Aug; 24(S1):38-69. PubMed ID: 31482779
[TBL] [Abstract][Full Text] [Related]
3. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.
de Bartolomeis A; Sarappa C; Magara S; Iasevoli F
Eur J Pharmacol; 2012 May; 682(1-3):1-11. PubMed ID: 22387855
[TBL] [Abstract][Full Text] [Related]
4. Multi-Target Approach for Drug Discovery against Schizophrenia.
Kondej M; Stępnicki P; Kaczor AA
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30309037
[TBL] [Abstract][Full Text] [Related]
5. Discovery and Development of Non-Dopaminergic Agents for the Treatment of Schizophrenia: Overview of the Preclinical and Early Clinical Studies.
Jankowska A; Satała G; Partyka A; Wesołowska A; Bojarski AJ; Pawłowski M; Chłoń-Rzepa G
Curr Med Chem; 2019; 26(25):4885-4913. PubMed ID: 31291870
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology.
Kaar SJ; Natesan S; McCutcheon R; Howes OD
Neuropharmacology; 2020 Aug; 172():107704. PubMed ID: 31299229
[TBL] [Abstract][Full Text] [Related]
7. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia.
Chavez-Noriega LE; Schaffhauser H; Campbell UC
Curr Drug Targets CNS Neurol Disord; 2002 Jun; 1(3):261-81. PubMed ID: 12769619
[TBL] [Abstract][Full Text] [Related]
8. Lumateperone: a new treatment approach for neuropsychiatric disorders.
Kumar B; Kuhad A; Kuhad A
Drugs Today (Barc); 2018 Dec; 54(12):713-719. PubMed ID: 30596390
[TBL] [Abstract][Full Text] [Related]
9. Neurobiological background for the development of new drugs in schizophrenia.
López-Muñoz F; Álamo C
Clin Neuropharmacol; 2011; 34(3):111-26. PubMed ID: 21586917
[TBL] [Abstract][Full Text] [Related]
10. The search for novel antipsychotics: pharmacological and molecular targets.
Sanger DJ
Expert Opin Ther Targets; 2004 Dec; 8(6):631-41. PubMed ID: 15584867
[TBL] [Abstract][Full Text] [Related]
11. Biological hypotheses, risk factors, and biomarkers of schizophrenia.
Fišar Z
Prog Neuropsychopharmacol Biol Psychiatry; 2023 Jan; 120():110626. PubMed ID: 36055561
[TBL] [Abstract][Full Text] [Related]
12. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.
Heresco-Levy U
Expert Opin Emerg Drugs; 2005 Nov; 10(4):827-44. PubMed ID: 16262565
[TBL] [Abstract][Full Text] [Related]
13. Advancements in Non-Dopaminergic Treatments for Schizophrenia: A Systematic Review of Pipeline Developments.
Komatsu Y; Takehara M; Hart X; Takahashi Y; Hori S; Ueno F; Uchida H
Pharmacopsychiatry; 2024 May; ():. PubMed ID: 38710208
[TBL] [Abstract][Full Text] [Related]
14. Dopamine receptors and schizophrenia: contribution of molecular genetics and clinical neuropsychology.
Emilien G; Maloteaux JM; Geurts M; Owen MJ
Int J Neuropsychopharmacol; 1999 Sep; 2(3):197-227. PubMed ID: 11281990
[TBL] [Abstract][Full Text] [Related]
15. Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics.
Sumiyoshi T; Bubenikova-Valesova V; Horacek J; Bert B
Adv Ther; 2008 Oct; 25(10):1037-56. PubMed ID: 18839076
[TBL] [Abstract][Full Text] [Related]
16. New drug treatments for schizophrenia: a review of approaches to target circuit dysfunction.
Howes OD; Dawkins E; Lobo MC; Kaar SJ; Beck K
Biol Psychiatry; 2024 May; ():. PubMed ID: 38815885
[TBL] [Abstract][Full Text] [Related]
17. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
Mirza NR; Peters D; Sparks RG
CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557
[TBL] [Abstract][Full Text] [Related]
18. Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis.
de Bartolomeis A; Fiore G; Iasevoli F
Curr Pharm Des; 2005; 11(27):3561-94. PubMed ID: 16248808
[TBL] [Abstract][Full Text] [Related]
19. [New pharmacological approaches to the treatment of schizophrenia].
Uzbay IT
Turk Psikiyatri Derg; 2009; 20(2):175-82. PubMed ID: 19504368
[TBL] [Abstract][Full Text] [Related]
20. The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia.
Na KS; Jung HY; Kim YK
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():277-86. PubMed ID: 23123365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
